The Amaka Chiwuike-Uba Foundation has decried the soaring cost of drugs for the management of asthmatic patients and the death of specialized doctors in Nigeria.
Asthma, which is a chronic inflammatory disease of the airways, is one of the most common non-communicable diseases worldwide and a leading cause of avoidable suffering and death.
Chairman of the foundation, Prof. Chiwuike Uba, told newsmen in a press briefing on Friday in Enugu, that in Nigeria, “the scale of the problem is sobering”.
Prof. Uba noted that with an estimated15 million – 20 million patients, the country carries one of the heaviest national burden of asthma globally.
According to him, urban prevalence rates range from 10 to 13 percent among children and young adults, while rural communities record slightly lower but still significant figures.
He said that “yet, Nigeria has fewer than 80 registered respiratory physicians, equivalent to just one specialist for every 2.3 million citizens.
“Most patients are therefore managed by general health practitioners who often lack access to spirometry, the diagnostic gold standard.
“A national audit revealed that only a handful of hospitals and private centers own functional spirometers, and even fewer employ staff trained to use them effectively.
“The consequences are tragic: thousands of avoidable deaths each year, particularly among the young.
“In schools, asthma remains one of the leading causes of absenteeism, undermining educational attainment and limiting opportunities for millions of children.”
Read also:
ACUF Foundation urges govts, stakeholders to cover gap in asthma treatment
Respiratory diseases a silent epidemic in Africa – DUFUHS Vice Chancellor raises alarm
Kaduna state to recruit 1,800 health workers to strengthen primary healthcare
Prof. Uba said that the economic burden of asthma is staggering, adding that average direct treatment costs range from $309 to $368 per patient annually, with medicines accounting for nearly 90 percent of the expense.
He noted that for households living below the poverty line, asthma treatment consumes more than 30 percent of annual income, forcing families to ration inhalers, skip doses or abandon treatment altogether.
“Indirect costs further compound the problem; missed school days, lost work productivity and premature deaths. Drug affordability remains a central challenge.
“In Nigeria, the cost of a salbutamol (Ventolin) inhaler has surged from around ₦3,500 to more than ₦7,500 in just two years, with some brands priced as high as between ₦15,000 and N20,000.
“Long-term controller inhalers often exceed ₦25,000, far beyond the reach of most citizens who pay out-of-pocket,” Prof. Uba added.
He urged the federal and state governments as well as health partners to collaborate to reduce the financial burden of asthmatic patients and promote specialised studies and research into the ailment.
